Best antihypertensive strategies to improve blood pressure control in Latin America: Position of the Latin American Society of Hypertension

Journal of Hypertension

Volumn 36, Issue 2, 2018, Pages 208-220

  Coca, Antonio ^a   López Jaramillo, Patricio ^b,c   Thomopoulos, Costas ^d   Zanchetti, Alberto ^e  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSIDAD DE SANTANDER   (Colombia)

^c School of Engineering Sciences and Industry   (Ecuador)

^d HELENA VENIZELOU HOSPITAL   (Greece)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

access to health systems; antihypertensive drugs; antihypertensive strategies in low income countries; availability of antihypertensive drugs

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO;

ALL CAUSE MORTALITY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; LOW INCOME COUNTRY; PRIORITY JOURNAL; SOUTH AND CENTRAL AMERICA; BLOOD PRESSURE; MEDICAL SOCIETY; PRACTICE GUIDELINE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; LATIN AMERICA; SOCIETIES, MEDICAL;

EID: 85039716236     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000001593     Document Type: Article

References (42)

1. Forouzanfar MH, Alexander L, Anderson HR, Bachman VF, Biryukov S, Brauer M, et al., GBD 2013 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386:2287-323.
2. He J, Gu D, Chen J, Wu X, Kelly TN, Huang JF, et al. Premature deaths attributable to blood pressure in China. Lancet 2009; 374:1765-1772.
3. Lopez-Jaramillo P, Sanchez R, Diaz M, Cobos L, Bryce A, Parra-Carrillo JZ, et al. Latin America consensus on hypertension in patients with diabetes type 2 and metabolic syndrome. J Hypertens 2013; 31:223-238.
4. Collins R, Peto R, MacMahon S, Godwin J, Qizilbash N, Hebert P, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-Term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335:827-839.
5. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, metaanalyses, and meta-regression analyses of randomized trials. J Hypertens 2014; 32:2285-2295.
6. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310:959-968.
7. Borzecki AM, Berlowitz DR. Management of hypertension and diabetes: Treatment goals, drug choices, current practice, and strategies for improving care. Curr Hypertens Rep 2005; 7:439-449.
8. Khatib R, Schwalm JD, Yusuf S, Haynes RB, McKee M, Khan M, et al. Patient and healthcare provider barriers to hypertension awareness, treatment and follow up: A systematic review and meta-Analysis of qualitative and quantitative studies. PLoS One 2014; 9:e8423.
9. Maimaris W, Paty J, Perel P, Legido-Quigley H, Balabanova D, Nieuwlaat R, et al. The influence of health systems on hypertension awareness, treatment, and control: A systematic literature review. PLoS Med 2013; 10:e1001490.
10. Legido-Quigley H, Camacho Lopez PA, Balabanova D, Perel P, Lopez-Jaramillo P, Nieuwlaat R, et al. Patients knowledge, attitudes, behaviour and healthcare experiences on the prevention, detection, management and control of hypertension in Colombia: A qualitative study. PLoS One 2015; 10:e0122112.
11. Khatib R, McKee M, Shannon H, Chow C, Rangarajan S, Teo K, et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and lowincome countries: An analysis of the PURE study data. Lancet 2016; 387:61-69.
12. Avezum A, Oliveira GB, Lanas F, Lopez-Jaramillo P, Diaz R, Miranda JJ, et al. Secondary CV prevention in South America in a community setting: The PURE study. Glob Heart 2016; [Epub ahead of print] doi: 10.1016/j.gheart.2016.06.001.
13. WHO. Global action plan for the prevention and control of no communicable diseases 2013-2020. Geneva: World Health Organization; 2013.
14. Patel P, Ordunez P, DiPette D, Escobar MC, Hassell T, Wyss F, et al. Improved blood pressure to reduce cardiovascular disease morbidity and mortality: The Standardized Hypertension Treatment and Prevention Project. J Clin Hypertens (Greenwich) 2016; 18:1284-1294.
15. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension 4. Effects of various classes of antihypertensive drugs. Overview and meta-Analyses. J Hypertens 2015; 33:195-211.
16. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressurelowering on outcome incidence in hypertension: 5. Head-To-head comparisons of various classes of antihypertensive drugs-overview and meta-Analyses. J Hypertens 2015; 33:1321-1341.
17. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressurelowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: metaanalyses of randomized trials. J Hypertens 2016; 34:1921-1932.
18. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al., 2013 ESH/ESC Guidelines for the Management of Arterial Hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281-1357.
19. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy vs. monotherapy in reducing blood pressure: meta-Analysis on 11 000 participants from 42 trials. Am J Med 2009; 122:290-300.
20. Corrao G, Parodi A, Zambon A, Heiman F, Filippi A, Cricelli C, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens 2010; 28:1584-1590.
21. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet 2007; 370:829-840.
22. PROGRESS Collaborative Group. Randomised trial of a perindopril based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033-1041.
23. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A. The Felodipine Event Reduction (FEVER) Study: A randomized long-Term placebo controlled trial in Chinese hypertensive patients. J Hypertens 2005; 23:2157-2172.
24. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417-2428.
25. ALLHAT Officers and Co-Ordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
26. Dalhof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Aulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required vs. atenolol adding bendroflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA) a multicentre randomised controlled trial. Lancet 2005; 366:895-906.
27. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al., LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359:995-1003.
28. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353:611-616.
29. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354:1751-1756.
30. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Sylversten JO, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study. Lancet 2000; 356:359-365.
31. SHEP Co-operative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:3255-3264.
32. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986; 293:1145-1151.
33. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338:1281-1285.
34. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24:3-10.
35. Ogihara T, Saruta T, Rakugi H, Saito I, Shimamoto K, Matsuoka H, et al. Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: A randomized, controlled trial. J Hypertens 2014; 32:2054-2063.
36. Wang W, Ma LY, Liu MB, Deng Q, Zhang YQ, Li W, et al. Effects of amlodipine plus telmisartan or amlodipine plus amiloride regimen on blood pressure control in hypertensive patients: preliminary report of Chinese Hypertension Intervention Efficacy (CHIEF) trial. Zhonghua Xin Xue Guan Bing Za Zhi 2009; 37:701-707.
37. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547-553.
38. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
39. Parving HH, Brenner BM, McMurray JJV, de Zeeuw D, Haffer SM, Solomon SD. Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367:2204-2213.
40. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369:1892-1903.
41. Gupta AK, Arshad S, Poulter NR. Compliance, safety and effectiveness of fixed-dose combinations of antihypertensive agents: A metaanalysis. Hypertension 2010; 55:399-407.
42. Coca A, Agabiti-Rosei E, Cifkova R, Manolis AJ, Redón J, Mancia G. The polypill in cardiovascular prevention: evidence, limitations and perspective. A position paper of the European Society of Hypertension. J Hypertens 2017; 35:1546-1553.